TSX open
Loading markets…

Advertisement

Stocks

Roche Holding (SWX:ROP) Ebola Testing Support Keeps Fair Value In Focus

By Wealth Awesome -

Follow live quotes and coverage.

Stocks & ETFs:ROP.US

Follow ROP

Photos provided by Pexels

Roche Holding's support for Ebola testing is sparking discussions about fair value.

Roche's recent initiative to support Ebola testing has caught attention regarding its fair value. This news comes amid ongoing discussions about Roper Technologies’ strategic moves and their impact on shareholders.

Investor takeaway: Keep an eye on how Roche's developments might affect perceptions of value in related sectors.

Advertisement

Roper Technologies Inc

ROP.US

Full stock page →

ROP.US

Roper Technologies Inc

Source:WealthAwesomeWealthAwesome
↑ $6.16 (1.72%)
120 day period
$314.67$369.90$425.13Apr 20Jul 16Oct 8

Market cap

$35.46B

P/E

15.1x

Div. yield

0.98%

Div. / share

$3.56

52W high

$514.14

52W low

$304.43

1W change

+0.71%

Beta

0.75

Analyst Price Targets

Based on 19 analysts covering ROP · as of Oct 5, 2026

📈

Wall Street analysts forecast ROP stock price to rise 20.6% over the next 12 months.

Consensus

Buy

3.58 / 5.00

Avg. Target

C$439.43

+20.6% Upside

Current Price

C$364.23

Last close

Analyst Breakdown (19 analysts)

Strong Buy 7
Hold 10
Sell 1
Strong Sell 1
Compare analyst targets →

Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.

Wealth Awesome Price Forecast

WA Model

Statistical 90-day price range based on ROP's historical volatility

HistoricalForecast68%95%
C$274.93C$330.84C$386.75C$442.66C$498.57C$554.48TodayJun 2Aug 6Oct 8Nov 20Jan 3Feb 15

30-Day Vol

26.8%

Annualized

90-Day Vol

31.0%

Annualized

Trend (90d)

+19.6%

Annualized drift

90d Mean

C$390.62

Expected price

HorizonExpected68% Range (1σ)
30 trading daysC$372.82C$339.85 – C$408.99
60 trading daysC$381.62C$334.78 – C$435.01
90 trading daysC$390.62C$332.74 – C$458.57

Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.

Advertisement

Roper Technologies Shares Up 1.58% Amid Recent News

Roper Technologies closed at US$365.44, with a trading volume of 51,212 shares, slightly below its 20-day average.

Roche's Ebola Testing Support Announced

Roche Holding has announced its support for Ebola testing, leading to renewed discussions about its fair value. This aligns with Roper Technologies (ROP.US), which closed at US$365.44, reflecting a 1.58% increase in its share price. In the past week, Roper's stock has gained 0.71%, but it has decreased by 7.71% over the past month and 15.55% year-to-date. Roche's initiative may indirectly affect how investors view fair value in Roper and similar companies.

Advertisement

Roper Technologies' Recent Trading Activity

Roper Technologies (ROP.US) saw its share price rise by 1.58%, closing at US$365.44. The trading volume was 51,212 shares, about 0.98 times its 20-day average of 890,431 shares, indicating lower trading activity compared to recent trends. The stock is currently below its 50-day moving average of US$390.53, showing a 6.4% decline, but is slightly above its 200-day moving average of US$368.30, which is 0.8% higher. The 52-week range for Roper is between US$304.43 and US$514.14, positioning the current price at about 29% of this range.

Market Sentiment and Future Considerations

As discussions about fair value continue, investors should pay attention to how Roche's actions might influence market sentiment toward Roper Technologies. Analysts have an average target price of US$439.43 for Roper, suggesting a potential upside of 20.2% from current levels. The company has a P/E ratio of 15.10, reflecting its valuation in relation to earnings, and a profit margin of 30.2% contributes to its financial stability. Roper's return on equity (ROE) stands at 13.1%, indicating efficient management of equity capital.

Advertisement

Wealth Awesome
Written by

Wealth Awesome

Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.

View Full Profile →

✅ Reviewed by Certified Financial Professionals

This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.

Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.

📊 Data AccuracyVerified sources
🇨🇦 Canadian FocusLocal expertise
🔍 Fact-CheckedEditorial review

⚠️ Professional Disclaimer

This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.

Published: October 9, 2026
Last Updated: October 9, 2026

Core portfolio

Awesome Portfolio™

14.8% a year since 2017, against 9.7% for the S&P/TSX Composite. Ten stocks, easy to manage. We update it once a month.

Annualized

+14.8%

Awesome Portfolio™

+9.7%

S&P/TSX

+5.0 pp better a year

Total return

+254%

Awesome Portfolio™

+134%

S&P/TSX

+119 pp better than the TSX

2017-07-31 to 2026-09-29, dividends reinvested, before fees and tax.

Awesome Portfolio™S&P/TSX CompositeCumulative return · 2017-07-31–2026-09-29
-11.7%42.5%96.7%150.9%205.1%259.3%Jul 17Oct 19Feb 22Jun 24Sep 26

Sponsored links

Advertisement